The most common grade 3 or worse adverse events in the olaparib group were fatigue ( in ten [ 7 % ] patients in the olaparib group vs four [ 3 % ] in the placebo group ) and anaemia ( seven [ 5 % ] vs one [ < 1 % ] ) .